anthrax < anti < antiangiogenic

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by anti

Number of relevant bibliographic references: 1352.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000014 (2020)	Puja Mehta ; Jessica J. Manson	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000020 (2020)	Jared Radbel [États-Unis] ; Navaneeth Narayanan [États-Unis] ; Pinki J. Bhatt [États-Unis]	Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.
000023 (2020)	Yehyun Park [Corée du Sud] ; Jae Hee Cheon [Corée du Sud]	Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
000030 (2020)	Gulzhan Trimova ; Kaoru Yamagata ; Shigeru Iwata ; Shintaro Hirata [Japon] ; Tong Zhang ; Fumi Uemura ; Minoru Satoh [Japon] ; Norma Biln ; Shingo Nakayamada ; Walter P. Maksymowych ; Yoshiya Tanaka	Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages
000032 (2020)	Marc Feldmann [Royaume-Uni] ; Ravinder N. Maini [Royaume-Uni] ; James N. Woody [États-Unis] ; Stephen T. Holgate [Royaume-Uni] ; Gregory Winter [Royaume-Uni] ; Matthew Rowland [Royaume-Uni] ; Duncan Richards [Royaume-Uni] ; Tracy Hussell [Royaume-Uni]	Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
000038 (2020)	Maria C. Cid [Espagne] ; Roberto Ríos-Garcés [Espagne] ; Nekane Terrades-García [Espagne] ; Georgina Espígol-Frigolé [Espagne]	Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
000042 (2020)	Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis]	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
000044 (2020)	Ernest H. Choy [Royaume-Uni] ; Fabrizio De Benedetti [Italie] ; Tsutomu Takeuchi [Japon] ; Misato Hashizume [Japon] ; Markus R. John [Suisse] ; Tadamitsu Kishimoto [Japon]	Translating IL-6 biology into effective treatments
000048 (2020)	Hazan Karadeniz [Turquie] ; Asl Han Avano Lu Güler [Turquie] ; Nuh Atas [Turquie] ; Hasan Sat [Turquie] ; Reyhan Bilici Salman [Turquie] ; Hakan Babaoglu [Turquie] ; Abdurrahman Tufan [Turquie]	Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review.
000050 (2020)	Daichi Fukaya [Japon] ; Tsutomu Inoue [Japon] ; Yuta Kogure [Japon] ; Hiroshi Kajiyama [Japon] ; Keisuke Ishizawa [Japon] ; Takeru Seto [Japon] ; Hajime Hasegawa [Japon] ; Toshihide Mimura [Japon] ; Hirokazu Okada [Japon]	Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases.
000052 (2020)	Yasuhiko Hirabayashi [Japon]	Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis.
000053 (2020)	Jean-Marie Michot [France] ; Laurence Albiges [France] ; Nathalie Chaput [France] ; Veronique Saada [France] ; Fanny Pommeret [France] ; Franck Griscelli [France] ; Corinne Balleyguier [France] ; Benjamin Besse [France] ; Aurélien Marabelle [France] ; Florence Netzer [France] ; Mansouria Merad [France] ; Caroline Robert [France] ; Fabrice Barlesi [France] ; Bertrand Gachot [France] ; Annabelle Stoclin [France]	Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
000054 (2020)	Rongda Li [République populaire de Chine] ; Qi Wan [République populaire de Chine] ; Pan Chen [République populaire de Chine] ; Shufen Mao [République populaire de Chine] ; Qiuju Wang [République populaire de Chine] ; Xiaoxin Li [République populaire de Chine] ; Yi Yang [République populaire de Chine] ; Li Dong [République populaire de Chine]	Tocilizumab treatment in Felty's syndrome.
000062 (2020)	Athimalaipet V. Ramanan [Royaume-Uni] ; Andrew D. Dick [Royaume-Uni] ; Catherine Guly [Royaume-Uni] ; Andrew Mckay [Royaume-Uni] ; Ashley P. Jones [Royaume-Uni] ; Ben Hardwick [Royaume-Uni] ; Richard W J. Lee [Royaume-Uni] ; Matthew Smyth [Royaume-Uni] ; Thomas Jaki [Royaume-Uni] ; Michael W. Beresford [Royaume-Uni]	Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial
000063 (2020)	Mitsuhiro Akiyama [Japon] ; Yuko Kaneko [Japon] ; Tsutomu Takeuchi [Japon]	Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review.
000076 (2020)	Philip George [Nouvelle-Zélande] ; Nathaniel Dasyam [Nouvelle-Zélande] ; Giulia Giunti [Nouvelle-Zélande] ; Brigitta Mester [Nouvelle-Zélande] ; Evelyn Bauer [Nouvelle-Zélande] ; Bethany Andrews [Nouvelle-Zélande] ; Travis Perera [Nouvelle-Zélande] ; Tess Ostapowicz [Nouvelle-Zélande] ; Chris Frampton [Nouvelle-Zélande] ; Peng Li [République populaire de Chine] ; David Ritchie [Australie] ; Catherine M. Bollard [États-Unis] ; Ian F. Hermans [Nouvelle-Zélande] ; Robert Weinkove [Nouvelle-Zélande]	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
000083 (2020)	Wen Zhang [République populaire de Chine] ; Yan Zhao [République populaire de Chine] ; Fengchun Zhang [République populaire de Chine] ; Qian Wang [République populaire de Chine] ; Taisheng Li [République populaire de Chine] ; Zhengyin Liu [République populaire de Chine] ; Jinglan Wang [République populaire de Chine] ; Yan Qin [République populaire de Chine] ; Xuan Zhang [République populaire de Chine] ; Xiaowei Yan [République populaire de Chine] ; Xiaofeng Zeng [République populaire de Chine] ; Shuyang Zhang [République populaire de Chine]	The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China
000087 (2020)	Wanhai Ke ; Li Zhang ; Yan Dai	The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
000099 (2020)	Carlo Perricone [Italie] ; Paola Triggianese [Italie] ; Elena Bartoloni [Italie] ; Giacomo Cafaro [Italie] ; Angelo F. Bonifacio [Italie] ; Roberto Bursi [Italie] ; Roberto Perricone [Italie] ; Roberto Gerli [Italie]	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
000110 (2020)	Anna Gluba-Brz Zka ; Beata Franczyk ; Robert Olszewski ; Jacek Rysz	The Influence of Inflammation on Anemia in CKD Patients
000126 (2020)	E C Schwaneck [Allemagne] ; R. Renner [Allemagne] ; L. Junker [Allemagne] ; H-P Tony [Allemagne] ; S. Kleinert [Allemagne] ; M. Gernert [Allemagne] ; M. Schmalzing [Allemagne] ; O. Gadeholt [Allemagne]	T cells, natural killer cells, and γδT cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "anti" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "anti" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    anti
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021